April 7, 2024
E3 Pairing and Structural Mechanisms Underlying Anti-Tumor Activity of Clinical STAT3 Degrader KT-333
American Association for Cancer Research (AACR) 2024 Annual Meeting
Read More
December 10, 2023
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Hematology (ASH) Annual Meeting and Exposition 2024
CTCL
LGL-L
PTCL
Solid Tumors
Read More
June 14, 2023
Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors
International Conference on Malignant Lymphoma (ICML) 2023
CTCL
LGL-L
PTCL
Solid Tumors
Read More
December 12, 2022
Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader
American Society of Hematology Annual Meeting and Expo
CTCL
Read More
October 19, 2022
KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo
20th Annual Discovery on Target Conference
Liquid Tumors
Solid Tumors
Read More
June 1, 2022
Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CTCL
LGL-L
PTCL
Solid Tumors
Read More
December 13, 2021
A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers
The 63rd Annual ASH Meeting and Exposition
Liquid Tumors
Read More
December 13, 2021
Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens
The 63rd Annual ASH Meeting and Exposition
Liquid Tumors
Read More
November 12, 2021
Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition
SITC 2021
Liquid Tumors
Solid Tumors
Read More
October 27, 2021
Understanding PK/PD for Development of STAT3 Degraders in Oncology Indications
4th Annual TPD Summit
Liquid Tumors
Solid Tumors
Read More